Diabetes and the Kidney: Diabetic Nephropathy: Prevention, Diagnosis, Treatment

Diabetes and the Kidney: Diabetic Nephropathy: Prevention, Diagnosis, Treatment

Volumn , Issue , 2005, Pages 1-132

  Hasslacher, Christoph ^a   Böhm, Sonja ^a  

^a Heidelberg ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84872969121     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/0470021616     Document Type: Book

References (14)

1. Hasslacher C, Ritz E, Wahl P, Michael C. Similar risks of nephropathy in patients with type I or type II diabetes mellitus. Nephrol Dial Transpl 1989; 4: 859-863.
2. Nordwall M, Bojestig M, Arnqvist H, Ludvisson J. Persistent decrease in nephropathy in type I diabetes. Diabetologia 2000; 43: A253.
3. Hironaka K, Makino H, Yamasaki Y, Ota Z. Renal basement membranes by ultra-high-resolution scanning electron microscopy. Kidney Int 1993; 43: 334-335.
4. The Diabetes Control and Complications Trial Research Group. Effect of intensive therapy on the development and progression of diabetic nephropathy in the diabetes control and complications trial. Kidney Int 1995; 47: 1703-1720.
5. The Diabetes Control and Complications Trial Research Group. The absence of a glycemic threshold for the development of long-term complications: the perspective of the diabetes control and complications trial. Diabetes 1996; 45: 1289-1298.
6. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 2000; 342: 381-389.
7. Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kunamoto study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000; 23(suppl 2): B21-B29.
8. Adler A, Stratton I, Neil H, Yudkin J, Matthews D, Dull C, Wright A, Turner R, Holman R. Associations of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. Br Med J 2000; 321: 412.
9. Lam K, Cheng I, Janus E, Pang R. Cholesterol-lowering therapy may retard the progression of diabetic nephropathy. Diabetologia 1995; 38:604-609.
10. Gaede P, Vedel P, Parving HH, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria:the Steno type 2 randomised study. Lancet 1999; 353: 617-622.
11. Klein R, Klein B, Moss S, DeMets D. Proteinuria in diabetes. Arch Intern Med 1988; 148: 181-186.
12. Sawicki P, Didjurgeit U, Muhlhauser I, Bender R, Heinemann L, Berger M. Smoking is associated with progression of diabetic nephropathy. Diabetes Care 1994; 17: 126-131.
13. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
14. Hasslacher C, Koops S, Ruderich F, Weise D. Course of nephropathy and prognosis of proteinuric Type 2 diabetic patients over 3 decades (1970-2000). Diabetologia 2001; 44: Suppl 1; A 269.